Franklin Biolabs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Franklin Biolabs is a specialized preclinical CRO focused exclusively on advanced therapies, including cell and gene, RNA, and biologics. The company has established a strong reputation with a 100% successful IND rate since its founding, supporting over 1,000 clients in more than 30 countries. Its integrated service model combines research vector production (AAV, lentivirus, adenovirus), comprehensive bioanalytics, and preclinical toxicology under one roof, aiming to reduce development timelines to 18-24 months for IND readiness. The 2026 acquisition of certain capabilities from the prestigious Penn Vector Core underscores its growing expertise and market position.

DiagnosticsInfectious Disease

Technology Platform

Integrated preclinical CRO platform for advanced therapies, combining viral vector production (AAV, lentivirus, adenovirus), CMC analytics, preclinical/translational toxicology studies, and specialized bioanalytics (immunogenicity, biodistribution) under one roof.

Opportunities

The company is poised to benefit from the rapid expansion of the global cell and gene therapy market, with increasing demand for specialized, integrated preclinical services.

Its recent expansion into lentiviral and adenoviral production opens doors to the large and growing cell therapy (e.g., CAR-T) and oncolytic virus sectors.

Risk Factors

Key risks include intense competition from both large global CROs and niche players, dependence on the funding and success of the broader advanced therapy sector, and operational execution risk where any failure in quality or timelines could damage its critical reputation and 100% IND success rate claim.

Competitive Landscape

Franklin competes in the specialized preclinical CRO space for advanced therapies, facing competition from large, diversified CROs (e.g., Charles River, LabCorp) and smaller, focused players. Its differentiation lies in its fully integrated service model, deep viral vector expertise (bolstered by the Penn Vector Core acquisition), and exclusive focus on cell/gene/RNA therapies.

More companies in Cell & Gene Therapy →More companies in United States →